Skip to main content
    U

    Uniqure NV (QURE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $21.88
    -1.93 (-8.11%)

    Market Cap: $1.67B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Uniqure NV (QURE) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Uniqure NV reported EPS of -$0.88, below the -$0.84 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    -5.33%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.89
    Range-$1.60 - -$0.33
    14 analysts
    Revenue Consensus
    $8.13M
    Range$3.43M - $17.54M
    12 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$1.00
    Range-$1.39 - -$0.84
    5 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.08+7.5%
    60d ago-$1.03+3.5%
    30d ago-$1.04+4.4%
    7d ago-$1.04+4.4%
    Current-$1.00
    Revenue Consensus
    $3.83M
    Range$1.69M - $4.90M
    4 analysts

    Next Report

    QURE's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    QURE Earnings Call

    The latest QURE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, QURE beat 21, missed 18 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $5.20M, up 40.5% from $3.70M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.88-$0.84-$1.05 - -$0.66-4.76%MissN/A112 up, 4 downNov 4, 2026$5.20M
    Jun 30, 2026-$1.22-$0.81N/A-50.62%MissN/A103 up, 4 downJul 29, 2026$5.84M
    Mar 31, 2026-$0.73-$0.75-$0.91 - -$0.66+2.67%BeatN/A91 up, 0 downMay 5, 2026$3.56M
    Dec 31, 2025-$0.47-$0.92N/A+48.31%BeatN/A103 up, 0 downMar 2, 2026$5.57M
    Sep 30, 2025-$1.19-$0.75-$0.91 - -$0.55-58.67%MissN/A107 up, 0 downNov 10, 2025$3.70M
    Jun 30, 2025-$0.60-$0.76-$0.91 - -$0.60+21.05%BeatN/A103 up, 0 downJul 29, 2025$5.26M
    Mar 31, 2025-$0.73-$0.93-$1.42 - -$0.57+21.51%BeatN/A103 up, 0 downMay 9, 2025$1.57M
    Dec 31, 2024-$1.44-$0.52-$1.47 - $1.09-178.82%MissN/A8N/AFeb 27, 2025$5.22M
    Sep 30, 2024-$0.84-$0.93-$1.38 - -$0.32+9.68%BeatN/A110 up, 0 downNov 5, 2024$2.29M
    Jun 30, 2024-$1.08-$1.16-$1.61 - -$0.69+6.90%BeatN/A101 up, 0 downAug 1, 2024$11.13M
    Mar 31, 2024-$1.26-$1.16-$1.64 - -$0.90-8.62%MissN/A130 up, 0 downMay 7, 2024$8.48M
    Dec 31, 2023-$1.53-$1.46-$1.89 - -$0.61-4.79%Miss-1120.0%130 up, 0 downFeb 28, 2024$6.69M
    Sep 30, 2023-$1.75-$0.72-$1.75 - $1.26-143.06%MissN/A131 up, 0 downNov 7, 2023$1.41M
    Jun 30, 2023-$1.31$2.81-$1.79 - $8.10-146.62%MissN/A140 up, 0 downAug 1, 2023$2.42M
    Mar 31, 2023-$1.48-$0.87-$1.80 - $2.12-70.11%MissN/A150 up, 0 downMay 9, 2023$5.33M
    Dec 31, 2022$0.15-$0.89-$1.60 - $0.86+116.85%Beat-11.8%170 up, 0 downFeb 27, 2023$102.75M
    Sep 30, 2022-$1.03-$1.11-$1.34 - -$0.48+7.21%BeatN/A170 up, 0 downNov 2, 2022$1.45M
    Jun 30, 2022-$0.83-$0.91N/A+8.79%Beat-111.5%N/A0 up, 0 downAug 8, 2022$497000
    Mar 31, 2022-$0.95-$0.79-$1.29 - $1.16-20.25%MissN/A160 up, 0 downMay 2, 2022$1.79M
    Dec 31, 2021$0.17-$0.81-$1.14 - $1.06+120.99%BeatN/A170 up, 0 downFeb 25, 2022$57.69M
    Sep 30, 2021-$0.68-$0.91-$2.25 - -$0.62+25.27%BeatN/A15N/AOct 25, 2021$1.99M
    Jun 30, 2021$7.23$2.18-$1.01 - $9.41+231.65%BeatN/A16N/AJul 26, 2021$463.87M
    Mar 31, 2021-$0.75-$0.77-$1.13 - -$0.61+2.60%BeatN/A14N/AMay 10, 2021$454000
    Dec 31, 2020-$0.01$1.52-$1.21 - $9.17-100.66%MissN/A16N/AMar 1, 2021$33.73M
    Sep 30, 2020-$1.02-$0.76-$1.00 - $9.23-34.21%MissN/A15N/AOct 27, 2020$3.58M
    Jun 30, 2020-$0.82-$0.52-$0.97 - $0.27-57.69%MissN/A15N/AJul 30, 2020N/A
    Mar 31, 2020-$0.58-$0.73-$1.18 - -$0.72+20.55%BeatN/A16N/AApr 29, 2020$208000
    Dec 31, 2019-$0.96-$0.73-$0.93 - -$0.55-31.51%MissN/A15N/AMar 2, 2020$2.63M
    Sep 30, 2019-$0.52-$0.74-$0.87 - -$0.73+29.73%BeatN/A12N/AOct 28, 2019$1.05M
    Jun 30, 2019-$0.75-$0.67N/A-11.94%MissN/A10N/AJul 29, 2019$2.47M
    Mar 31, 2019-$0.66-$0.63-$0.95 - -$0.59-4.76%MissN/A9N/AApr 29, 2019$1.14M
    Dec 31, 2018-$0.59-$0.66-$0.75 - -$0.60+10.61%BeatN/A8N/AFeb 28, 2019$1.61M
    Sep 30, 2018-$0.52-$0.54N/A+3.70%BeatN/A8N/ANov 6, 2018$3.15M
    Jun 30, 2018-$0.49-$0.52N/A+5.77%BeatN/A8N/AAug 8, 2018$3.05M
    Mar 31, 2018-$0.49-$0.61N/A+19.67%BeatN/A3N/AApr 30, 2018$3.48M
    Dec 31, 2017-$0.91-$0.77-$0.88 - -$0.61-18.18%MissN/A6N/AMar 14, 2018$2.58M
    Sep 30, 2017-$0.34-$0.54-$0.85 - -$0.41+37.04%BeatN/A4N/ANov 1, 2017$2.26M
    Jun 30, 2017-$0.71-$0.71-$1.04 - -$0.370.00%In lineN/A5N/AAug 8, 2017$4.94M
    Mar 31, 2017-$0.74-$0.58N/A-27.59%MissN/AN/AN/AMay 9, 2017$3.32M
    Dec 31, 2016-$0.51-$0.56N/A+8.93%BeatN/AN/AN/AMar 15, 2017$9.13M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.99, after -$4.62 the year before. It was -$6.07 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.99N/A
    Dec 31, 2024-$4.62N/A
    Dec 31, 2023-$6.07N/A
    Dec 31, 2022-$2.66-144.6%
    Dec 31, 2021$5.97N/A
    Dec 31, 2020-$2.43N/A
    Dec 31, 2019-$2.89N/A
    Dec 31, 2018-$2.09N/A
    Dec 31, 2017-$2.70N/A
    Dec 31, 2016-$6.07N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,41718
    2026Q2Jun 30, 20265,66520
    2025Q4Dec 31, 20256,89415
    2025Q3Sep 30, 20254,19013
    2025Q2Jun 30, 20256,13814
    2025Q1Mar 31, 20256,69017

    2026Q3 Earnings Call

    Opening remarks

    Chiara Russo Senior Director of Investor Relations Thank you. Good morning, and thank you for joining us for uniQure's third quarter of 2026 earnings call. Earlier this morning, uniQure released its financial results for the third quarter of 2026, and our press release is available on the Investors and Media section of our website at unicure.com. Our 10-Q was also filed with the SEC earlier today. Joining me on the call this morning are Matt Kapusta, Chief Executive Officer; Dr. Walid Abi-Saab, Chief Medical Officer; Kylie O'Keefe, Chief Customer and Strategy Officer; and Christian Klemt, Chief Financial Officer. After our formal remarks, we'll open up for an analyst Q&A. Before we begin, please note that we'll be making forward-looking statements during this investor call. All statements other than statements of historical fact are forward-looking statements. They are based on management's beliefs and assumptions and on information available to management only as of the date of this conference call. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the factors described in uniQure's most recent SEC filings. Given these risks, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these statements even if information becomes available in the future. Now let me introduce Matt Kapusta, uniQure's CEO.

    Matthew Kapusta CEO Good morning, and thank you for joining us on today's call. For the families who have waited generations for treatment for Huntington's disease, this quarter brought meaningful progress. As we announced on Monday, the FDA has accepted our biologics license application for AMT-130 and granted priority review with a target PDUFA date of May 1, 2027. In the United Kingdom, the MHRA has also validated our marketing authorization application. These are the first such marketing applications for a disease-modifying therapy for Huntington's disease, and they bring patients and families one step closer to a treatment option. We greatly appreciate the engagement of both the FDA and the MHRA and their focus on the critical need for new therapies in Huntington's disease. I also want to acknowledge the commitment of our clinical, regulatory, and CMC teams, who prepared and submitted both applications in record time. And to every HD patient, family member, and investigator who has trusted us with their hope, thank you. In September, we shared additional data from our ongoing Phase I/II studies, including updated 36-month data from all 27 evaluable patients across the low- and high-dose cohorts and, for the first time, 48 months of follow-up after a single administration of AMT-130. These data continue to show meaningful, dose-dependent slowing of disease progression and reinforce our strong belief that AMT-130 has the potential to deliver treatment benefit to patients.

    Frequently Asked Questions About QURE

    Did QURE beat earnings estimates last quarter?

    No. Uniqure NV reported EPS of -$0.88 for the quarter ended Sep 30, 2026, below the -$0.84 estimate by 4.76%.

    What EPS do analysts expect from QURE next quarter?

    The consensus EPS estimate for Uniqure NV for the quarter ending Dec 31, 2026 is -$0.89 from 14 analysts, with estimates from -$1.60 to -$0.33.

    How often does QURE beat earnings estimates?

    Uniqure NV beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -24.92%.